Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Equity (Details Narrative)

Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands						1 Months Ended	3 Months Ended				12 Months Ended
	Jan. 15, 2020	Jan. 10, 2020	Oct. 16, 2019	Jul. 15, 2019	Jan. 25, 2019	Jan. 31, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Sep. 20, 2019
Shares granted											525,550
Received net proceeds											$ 434	$ 6,478
Proceeds from issuance of stock											$ 19,223
Preferred stock aggregate value							$ 1		$ 73	$ 1
Preferred stock dividend percentage											6.00%
Sale of stock											178,000	97,817
Proceeds from sale of stock											$ 700	$ 200
Series B Preferred Stock [Member]
Preferred stock adjusted conversion	$ 6.00
Company achieve revenue target						$ 34,000
Intrinsic value of beneficial conversion feature	$ 2,200
Intrinsic value of effective conversion price per share	$ 6.79
Sale of stock						20,000
Series B [Member]
Aggregate of shares issued											27,000
Preferred stock par/stated value											$ 0.01
Preferred stock adjusted conversion											$ 6.00
Preferred stock, shares issued								47,000			47,000	47,000
Series A [Member]
Aggregate of shares issued											270
Preferred stock par/stated value											$ 0.01
Value of preferred stock exchanged											$ 27,000
Preferred shares stated value											$ 100,000
Preferred stock adjusted conversion											$ 8.00
Preferred stock, shares issued								270			270	270
Underwriting Agreement [Member]
Aggregate of shares issued					933,334
Shares granted					1,400,000
Common stock price, per share					$ 7.50
Effective price per share					$ 6.975
Received net proceeds					$ 5,900
Security Purchase Agreement [Member] \| Investor [Member]
Business combination consideration shares			130
Business combination consideration amount			$ 13,000
Security Purchase Agreement [Member] \| Convertible Preferred Stock [Member]
Preferred price per share				$ 0.01
Preferred stock par/stated value				$ 100,000
Security Purchase Agreement [Member] \| Convertible Preferred Stock [Member] \| Maximum [Member]
Proceeds from preferred stock value				$ 27,000
Security Purchase Agreement [Member] \| 60 Newly Created Series A Preferred Stock [Member]
Business combination consideration shares				60
Business combination consideration amount				$ 6,000
Security Purchase Agreement [Member] \| 60 Newly Created Series A -1 Preferred Stock [Member]
Business combination consideration shares				80
Business combination consideration amount				$ 8,000
Proceeds from issuance of stock				$ 13,100
Security Purchase and Exchange Agreement [Member] \| Series B [Member]
Preferred price per share		$ 1,000
Preferred stock aggregate value		$ 20,000
Security Purchase and Exchange Agreement [Member] \| Series B [Member] \| 1315 Capital [Member]
Aggregate of shares issued		19,000
Preferred stock aggregate value		$ 19,000
Security Purchase and Exchange Agreement [Member] \| Series B [Member] \| Ampersand 2018 Limited Partnership [Member]
Aggregate of shares issued		1,000
Preferred stock aggregate value		$ 1,000
Equity Distribution Agreement [Member]
Aggregate offering price													$ 4,800
Fixed percentage of commission													3.00%